Abstract:Importance: Community-acquired pneumonia (CAP) results in approximately 1.4 million emergency department visits, 740 000 hospitalizations, and 41 000 deaths in the US annually. Observations: Community-acquired pneumonia can be diagnosed in a patient with 2 or more signs (eg, temperature >38 °C or ≤36 °C; leukocyte count <4000/μL or >10 000/μL) or symptoms (eg, new or increased cough or dyspnea) of pneumonia in conjunction with consistent radiographic findings (eg, air space density) without an alternative explanation. Up to 10% of patients with CAP are hospitalized; of those, up to 1 in 5 require intensive care. Older adults (≥65 years) and those with underlying lung disease, smoking, or immune suppression are at highest risk for CAP and complications of CAP, including sepsis, acute respiratory distress syndrome, and death. Only 38% of patients hospitalized with CAP have a pathogen identified. Of those patients, up to 40% have viruses identified as the likely cause of CAP, with Streptococcus pneumoniae identified in approximately 15% of patients with an identified etiology of the pneumonia. All patients with CAP should be tested for COVID-19 and influenza when these viruses are common in the community because their diagnosis may affect treatment (eg, antiviral therapy) and infection prevention strategies. If test results for influenza and COVID-19 are negative or when the pathogens are not likely etiologies, patients can be treated empirically to cover the most likely bacterial pathogens. When selecting empirical antibacterial therapy, clinicians should consider disease severity and evaluate the likelihood of a bacterial infection-or resistant infection-and risk of harm from overuse of antibacterial drugs. Hospitalized patients without risk factors for resistant bacteria can be treated with β-lactam/macrolide combination therapy, such as ceftriaxone combined with azithromycin, for a minimum of 3 days. Systemic corticosteroid administration within 24 hours of development of severe CAP may reduce 28-day mortality. Conclusions: Community-acquired pneumonia is common and may result in sepsis, acute respiratory distress syndrome, or death. First-line therapy varies by disease severity and etiology. Hospitalized patients with suspected bacterial CAP and without risk factors for resistant bacteria can be treated with β-lactam/macrolide combination therapy, such as ceftriaxone combined with azithromycin, for a minimum of 3 days.

Community-acquired pneumonia: The importance of the early detection of drug-resistant organisms

Community-acquired bacterial pneumonia in adults: An update

Incidence of drug-resistant pathogens in community-acquired pneumonia at a safety net hospital

Multidrug Resistant Gram-Negative Bacteria in Community-Acquired Pneumonia

Burden of Community-Acquired Pneumonia and Unmet Clinical Needs

Community-Acquired Pneumonia: A Review

Identify Drug-Resistant Pathogens in Patients with Community-Acquired Pneumonia

Advancements in the Management of Severe Community-Acquired Pneumonia: A Comprehensive Narrative Review

Isolation and Antimicrobial Resistance Patterns of Bacterial Pathogens from Community-Acquired Pneumonia at Adama Hospital Medical College, Adama, Ethiopia

Critical insights from recent outbreaks of Mycoplasma pneumoniae: decoding the challenges and effective interventions strategies

Antimicrobial Drug-Resistant Microbes Associated with Hospitalized Community-Acquired and Healthcare-Associated Pneumonia: A Multi-Center Study in Taiwan

Pathogenic bacterial profile and drug resistance analysis of community-acquired pneumonia in older outpatients with fever

Emerging Resistance of Gram Negative Pathogens in Community-Acquired Pneumonia

The Global Burden of Community-Acquired Pneumonia in Adults, Encompassing Invasive Pneumococcal Disease and the Prevalence of Its Associated Cardiovascular Events, with a Focus on Pneumolysin and Macrolide Antibiotics in Pathogenesis and Therapy

Epidemiology, Treatment, and Prevention of Nosocomial Bacterial Pneumonia

Improved Detection of Culprit Pathogens by Bacterial DNA Sequencing Affects Antibiotic Management Decisions in Severe Pneumonia

A case report of community-acquired Pseudomonas aeruginosa pneumonia complicated with MODS in a previously healthy patient and related literature review

Diagnostic and Prognostic Roles of Procalcitonin and Other Tools in Community-Acquired Pneumonia: A Narrative Review

A review of the value of point-of-care testing for community-acquired pneumonia

Current Status of Community-Acquired Pneumonia in Patients with Chronic Obstructive Pulmonary Disease

Atypical pathogen infection in community-acquired pneumonia.